Announcements Trials
Browse Landscape

Phase

Phase 3 1

Status

Completed 3Unknown 1Terminated 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Thoracic 1

Conditions

Thoracic Neoplasms 1Neoplasms 1Lung Neoplasms 1Lung Diseases 1Carcinoma, Non-Small-Cell Lung 1Carcinoma, Bronchogenic 1Bronchial Neoplasms 1

Interventions

Cisplatin 509Cyclophosphamide 360Carboplatin 352Radiotherapy 350Capecitabine 329Paclitaxel 325Oxaliplatin 324Gemcitabine 319Docetaxel 311Fluorouracil 283Drug Therapy 243apatinib 242Bevacizumab 229camrelizumab 214Etoposide 200Irinotecan 176Doxorubicin 175Leucovorin 161Dexamethasone 160sintilimab 142pembrolizumab 138anlotinib 136Pemetrexed 136Cytarabine 136toripalimab 129Neoadjuvant Therapy 122S 1 (combination) 120Vincristine 119Rituximab 117Radiosurgery 117

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Unknown × Interventional × TNFSF10 protein, human × Clear all
NCT03083743 2017-03-20

A Phase III Trial of Recombinant Human Apo-2 Ligand for Injection

Shanghai Gebaide Biotechnology Co., Ltd.

Phase 3 Unknown
417 enrolled
Thoracic

Bronchial Neoplasms, Carcinoma, Bronchogenic, Carcinoma, Non-Small-Cell Lung, Lung Diseases, Lung Neoplasms, Neoplasms, Thoracic Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡